SCHEMBL2292198

SCHEMBL2292198

O[C@H]1CCCC[C@@H]1O[C@H]1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@@H]1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 9/20 0.51
PTPN2 P17706 4/20 0.51
PTPN11 Q06124 4/20 0.51
SSTR1 P30872 1/20 0.49
SSTR2 P30874 1/20 0.49
SSTR4 P31391 1/20 0.49
SSTR3 P32745 1/20 0.49
SSTR5 P35346 1/20 0.49
NT5E P21589 1/20 0.48
GJB2 P29033 2/20 0.47
SLC6A2 P23975 2/20 0.47
CDC25B P30305 7/20 0.46
PTPN6 P29350 3/20 0.46
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12380733 1.00 PTPN1 (0.51) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL12380734 1.00 PTPN1 (0.51) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL2292205 1.00 PTPN1 (0.51) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL2287912 1.00 PTPN1 (0.51) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL2287910 1.00 PTPN1 (0.51) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL12380729 0.85 PTPN1 (0.51) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL12380731 0.85 PTPN1 (0.51) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL9117860 0.84 SSTR1 (0.53) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL9117871 0.84 SSTR1 (0.53) PTPN1PTPN2PTPN11SSTR1SSTR2
SCHEMBL8779233 0.83 SLC6A2 (0.42) PTPN1PTPN2PTPN11SSTR1SSTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989602-B2 having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosacccharide) activity; asthma, allergic rhinitis, dermatitis, psoriasis, inflammatory bowel disease including Crohn's disease and ulcerative colitis, rheumatoid arthritis, multiple sclerosis, diabetes, systemic lupus THE MALAGHAN INSTITUTE OF MEDICAL RESEARCH (NZ) 2011-08-02 US disclosed
US-20080249037-A1 Synthetic Molecules Having Immune Activity UNIVERSITY OF OTAGO (NZ) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249037-A1 Synthetic Molecules Having Immune Activity ALG1, PAG1, SIGLEC7 PTPN1 1017/4885PTPN2 1002/4885PTPN11 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.